TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05021822

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: Bilateral erector spinae plane block will be performed preoperatively under ultrasound guidance using 15 ml bupivacaine on each side
Study: NCT05493228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Precedex Injectable Product
Description: Precedex activates 2-adrenoceptors, and causes the decrease of sympathetic tone, with attenuation of the neuroendocrine and hemodynamic responses to anesthesia and surgery; it reduces anesthetic and opioid requirements; and causes sedation and analgesia. it is used before and/or during surgical

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: mixture of sodium chloride (salt) and water in solution with 0.90% w/v of NaCl
Study: NCT05499143

Intervention type: OTHER
Intervention: Online questionnaire
Description: Online questionnaire impact for DCD - Belgian version
Study: NCT05042362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elinzanetant (BAY3427080)
Description: 120 mg elinzanetant orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Elinzanetant (BAY3427080)
Description: 120 mg elinzanetant orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo orally once daily
Study: NCT04915079

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promoting Resilience in Stress Management (PRISM)
Description: PRISM is a novel resilience resource intervention consisting of five, one-on-one sessions lasting 30-50 minutes targeting specific teachable resilience skills: stress management, problem solving, goal setting, benefit finding, and meaning making. Sessions will occur at a time convenient to the patient with the first session to occur within 1 week of enrollment either while inpatient or if the patient is discharged, in the outpatient setting in-person or by HIPPA-compliant Zoom. After completion, participants will receive weekly booster contacts (invitations to practice reviewing certain skills) until the occurrence of a planned patient-clinician conversation, facilitated and arranged by study staff during the 5th session. All participants will receive paper worksheets to practice skills between sessions, plus access to a free, digital PRISM app (available only for patients enrolled in PRISM).
Study: NCT05750277

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evening Time-Restricted Eating
Description: Eating between 8am-6pm.
Study: NCT06105996

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interoceptive training
Description: There will be 6 interoceptive training sessions carried out over two months. Each training session will comprise two blocks, between which participants will undergo a self-paced, light physical activity that aims to enhance heartbeat perception and lasts 2 to 3 minutes. During the pre- and post-exercise block, each participant will complete cardiac interoceptive tasks, and for each trial, note their confidence in their answer on a visual analogue scale and then be given accurate feedback about their objective heartbeat perception accuracy and the accuracy of their subjective confidence rating, relative to their objective accuracy.
Study: NCT05869383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ophiochepalus striatus extract
Description: Ophiochepalus striatus extract 2x5 grams

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 2x5 grams
Study: NCT06539416

Intervention type: PROCEDURE
Intervention: MitraClip implantation
Description: The MitraClip is used to catch the leaky parts of the mitral valve, and it is tested to ensure the leak is reduced.

Intervention type: PROCEDURE
Intervention: MitraClip implantation
Description: The MitraClip is used to catch the leaky parts of the mitral valve, and it is tested to ensure the leak is reduced.
Study: NCT05927714

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Amnion-chorion Membrane
Description: Amnio-chorion membranes specifically for palatal wound healing following free soft tissue autografts (FTSA) procedures.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ActCel Cellulose Gauze
Description: When these products come in contact with blood, they convert to a gel that expands to cause direct pressure on blood vessels and control bleeding. ActCel is water-soluble and dissolves over a short time period. It can be removed easily when water, saline or hydrogen peroxide is applied.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ActCel Cellulose Gauze
Description: When these products come in contact with blood, they convert to a gel that expands to cause direct pressure on blood vessels and control bleeding. ActCel is water-soluble and dissolves over a short time period. It can be removed easily when water, saline or hydrogen peroxide is applied.
Study: NCT06353802

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Chronic non-specific neck pain and lumbar reposition sense
Description: In order to evaluate the lumbar joint repositioning error using the Joint Positioning Sense, the following guidelines were followed: (I) The participants were to stand with their arms at their sides, their feet externally rotated (about 20 degrees).~(II) With the feet flat on the floor and the arms resting on the front of the thighs, the person was seated in a height-adjustable seat that measured the length of the shank. (III) With a belt fastened, the iPhone® was positioned upright just above the iliac crest, (IV) the inclination of the inclinometer was 0°; (V) The inclinometer's 0° point was set as the initial position. (VI) The individual was passively guided by the assessor to a 30° flexion within the range of 0 to 30°; (VII) the subject was to memorize this position for 10 s; (VIII) the subject actively returned to the initial position. (IX) Subsequently, the participant was required to actively replicate the position three times.
Study: NCT06531811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8630 (test formulation) via test inhaler
Description: Participants will receive AZD8630 via test inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8630 (test formulation) via test inhaler
Description: Participants will receive AZD8630 via test inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8630 (reference formulation) via Monodose inhaler
Description: Participants will receive AZD8630 via Monodose inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8630 (reference formulation) via Monodose inhaler
Description: Participants will receive AZD8630 via Monodose inhaler.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test inhaler
Description: Participants will receive AZD8630 via test inhaler.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test inhaler
Description: Participants will receive AZD8630 via test inhaler.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monodose inhaler
Description: Participants will receive AZD8630 via Monodose inhaler.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monodose inhaler
Description: Participants will receive AZD8630 via Monodose inhaler.
Study: NCT06369883

Intervention type: DIAGNOSTIC_TEST
Intervention: Spine radiography
Description: Posterior-anterior and lateral spine radiography
Study: NCT05770908

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise program
Description: Therapeutic exercise program based on increasing resistance with elastic bands or weights. The programmes are composed of combinations of the following exercises:~* Scaption with elastic band.~* External rotation at 0º of abduction with elastic band.~* Internal rotation at 0º of abduction with elastic band.~* Shoulder protraction in supine position with weights.~* Low row with elastic band.~* Horizontal adduction stretching.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic exercise program
Description: Therapeutic exercise program based on increasing resistance with elastic bands or weights. The programmes are composed of combinations of the following exercises:~* Scaption with elastic band.~* External rotation at 0º of abduction with elastic band.~* Internal rotation at 0º of abduction with elastic band.~* Shoulder protraction in supine position with weights.~* Low row with elastic band.~* Horizontal adduction stretching.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimedia animation information
Description: Multimedia animation videos (including audio) showing the performance of the prescribed exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paper-based information
Description: Paper-based information showing the performance of the prescribed exercises, based on figures and a brief description of the exercise performance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Paper-based information
Description: Paper-based information showing the performance of the prescribed exercises, based on figures and a brief description of the exercise performance.
Study: NCT05277818

Intervention type: PROCEDURE
Intervention: Surgery lumbar disc herniation
Description: Surgery for a degenerative or traumatic mono-segmental lumbar disc herniation

Intervention type: PROCEDURE
Intervention: Surgery lumbar disc herniation
Description: Surgery for a degenerative or traumatic mono-segmental lumbar disc herniation
Study: NCT06076798

Intervention type: DEVICE
Intervention: ECG co-measurement
Description: Measure ECG with 12 lead device at same time that AFGen1 is monitoring ECG
Study: NCT06309485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WGI-0301 at MTD/RP2D dose IV infusion, QW
Description: WGI-0301 is a lipid nanoparticle preparation of Archexin®, a 20-mer oligonucleotide that is complementary to Akt-1 mRNA, formulated for the treatment of advanced HCC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WGI-0301 at MTD/RP2D -1 dose IV infusion, QW
Description: WGI-0301 is a lipid nanoparticle preparation of Archexin®, a 20-mer oligonucleotide that is complementary to Akt-1 mRNA, formulated for the treatment of advanced HCC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg PO, BID continuously
Description: Sorafenib is an oral multi-kinase inhibitor used for the treatment of hepatocellular carcinoma.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib 400 mg PO, BID continuously
Description: Sorafenib is an oral multi-kinase inhibitor used for the treatment of hepatocellular carcinoma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg PO, BID
Description: Sorafenib is an oral multi-kinase inhibitor used for the treatment of hepatocellular carcinoma.
Study: NCT05063123

Intervention type: DRUG
Group type: OTHER
Intervention: Flotetuzumab
Description: Flotetuzumab will be given after at least 2 intensive chemotherapy cycles and before the start of the conditioning regimen prior to allo-HCT.
Study: NCT04882033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy plus anlotinib
Description: Anlotinib: for cycle 1-6. P.O; QD; from days 1 to 14 in a 21-day cycle. 8mg in low-dose groups (3 subjects). 10mg in middle-dose groups (3 subjects). 12mg in high-dose groups (3 subjects).~Chemotherapy:~For cycle 1/4/5/6. Etoposide 100mg/m2, d1-3, q3w; Cisplatin 25mg/m2 d1-3, q3w. For cycle 2/3. Etoposide 50mg/m2, d1-3, q4w; Cisplatin 25mg/m2 d1-3, q4w.~Radiotherapy:~For cycle 2/3.Thoracic radiotherapy dose will be 2.0Gy per day, given 5 days a week, to cumulative dose of 60～66Gy.
Study: NCT06505083

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: modified stepping trainings
Description: step-up on box texture difference

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: modified stepping trainings
Description: step-up on box texture difference
Study: NCT05801419

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RETI-port/scan 21
Description: Pattern visual event-related potential and pattern electroretinogram on right eye (non-dilated pupil) at baseline, post e-cigarette vaping without nicotine and post e-cigarette vaping with nicotine.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zilia Ocular
Description: Eye fundus tissue oximetry measure on left eye (dilated pupil) at baseline, post e-cigarette vaping without nicotine and post e-cigarette vaping with nicotine.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCT-A
Description: Optical coherence tomography angiography measure on left eye (dilated pupil) at baseline, post e-cigarette vaping without nicotine and post e-cigarette vaping with nicotine.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Electronic cigarette without nicotine
Description: Vaping using an e-cigarette paired with an e-cigarette liquid vial without nicotine. Inhaling through the mouth and exhaling through the nose ten times. Inhalations must last 5 seconds and the participant has 5 minutes to do the 10 inhalations.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Electronic cigarette with nicotine
Description: Vaping using an e-cigarette paired with an e-cigarette liquid vial with nicotine. Inhaling through the mouth and exhaling through the nose ten times. Inhalations must last 5 seconds and the participant has 5 minutes to do the 10 inhalations.
Study: NCT06125067

Intervention type: PROCEDURE
Intervention: no peripheral block
Description: No peripheral block was applied. Standard multimodal analgesia method was applied.

Intervention type: PROCEDURE
Intervention: Fascia Iliaca Compartment Block
Description: Fascia Iliaca Compartment Block is performed with the patient in a supine position. A high-frequency (6-14 MHz) linear ultrasound probe is positioned transversely to locate the femoral artery in the inguinal crease. The hyperechoic femoral nerve is usually visualized lateral to the femoral artery, between the iliopsoas and fascia iliaca. The probe is manoeuvred in a cranial and caudal direction to capture high-quality images of the femoral nerve and fascia iliaca. Identification of the triangular-shaped sartorius muscle and anterior superior iliac spine (ASIS) is achieved by lateral movement of the probe. Post-skin disinfection, the needle tip is directed just beneath the fascia iliaca. Local anaesthetic is administered following negative pressure aspiration into the area. The local anaesthetic spreads towards the femoral nerve medially and towards the iliac process laterally.

Intervention type: PROCEDURE
Intervention: iPACK Block
Description: During the iPACK procedure, the patient assumes a supine position with the lower extremity flexed at the knee and abducted at the hip (in frog-leg position). The ultrasound transducer is placed in the lower third of the medial thigh, and then pushed backward and downward to visualize the gap between the popliteal artery and the femoral shaft, straight above the femoral condyles. After ensuring that the needle tip is placed 2 cm beyond the lateral border of the artery, local anaesthetic solution is administrated in divided doses to infiltrate the tissue space. The needle is then withdrawn after confirming negative aspiration.
Study: NCT06083688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-Piperaquine
Description: Treatment will be with DP (females less than 13 years old and all males) or chloroquine alone (females 13 years old or older).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: Treatment will be with CQ alone if female and 13 years old or older in both intervention arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: Treatment will be with CQ alone if female and 13 years old or older in both intervention arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine-amodiaquine
Description: Treatment in Arm 2 (females less than 13 years old and all males).
Study: NCT06354907

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Kids' Empowerment Program
Description: The 12-session KEP provides support and information while teaching children self-management skills based on techniques derived from a combination of best, evidence-based practices (e.g., using elements of cognitive behavioral therapy, behavioral activation, brief behavioral activation, and interpersonal therapy. Adjustment is enhanced with a comprehensive approach that strengthens cognition (how to think about things), changes behavior (problem solving or planning actions), and focuses on emotions (identifying and expressing feelings), social relationships (peers, parents, siblings), and physical health (de-stressing, exercise). Group leaders follow a training manual with developmentally appropriate scripts, instructions for behavioral applications in (e.g., craft or game activities) and practice plans.
Study: NCT05920135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBT-207
Description: BBT-207 given orally alone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBT-207
Description: BBT-207 given orally alone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBT-207
Description: BBT-207 given orally alone
Study: NCT06075810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBQ-167
Description: MBQ-167, an inhibitor of Rho GTPases Rac and Cdc42
Study: NCT05383872

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused Ultrasound (Exablate Model 4000)
Description: BBB opening via Exablate Type 2 system with microbubble resonators and drawing blood before and after opening
Study: NCT05886998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: Heparin sodium (Generic, 5000 IU/ml ampoules)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 0.9% sodium chloride solution (normal saline)
Study: NCT04082481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-988
Description: TAK-988 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-988
Description: TAK-988 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-988
Description: TAK-988 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-988
Description: TAK-988 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-988
Description: TAK-988 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-988 Placebo
Description: TAK-988 placebo-matching tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-988 Placebo
Description: TAK-988 placebo-matching tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-988 Placebo
Description: TAK-988 placebo-matching tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-988 Placebo
Description: TAK-988 placebo-matching tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-988 Placebo
Description: TAK-988 placebo-matching tablets.
Study: NCT06171282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant oncolytic herpes simplex virus type Ⅰ (R130)
Description: R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
Study: NCT05548413

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FamLit
Description: The FamLit (Family-focused and Literacy-sensitive strategy) is an interactive, multi-component intervention supported by the FamLit intervention Guide, including both spoken and printed materials written at a 4th-grade reading level for HF patients and their primary CPs.Three constructs guide the intervention, based on the Theory of Planned Behavior (TPB): 1) develop patient and CP positive attitudes through HF instruction and teach-back; 2) form positive subjective norms through coaching to improve patient and CP communication, support, and teamwork; and 3) increase perceived behavioral control through coaching and role-playing to empower patients and CPs to overcome individual barriers to adherence. This intervention also includes use of the SimpleMed+ electronic pillbox.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FamLit
Description: The FamLit (Family-focused and Literacy-sensitive strategy) is an interactive, multi-component intervention supported by the FamLit intervention Guide, including both spoken and printed materials written at a 4th-grade reading level for HF patients and their primary CPs.Three constructs guide the intervention, based on the Theory of Planned Behavior (TPB): 1) develop patient and CP positive attitudes through HF instruction and teach-back; 2) form positive subjective norms through coaching to improve patient and CP communication, support, and teamwork; and 3) increase perceived behavioral control through coaching and role-playing to empower patients and CPs to overcome individual barriers to adherence. This intervention also includes use of the SimpleMed+ electronic pillbox.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Participants in this group will talk with an interventionist to discuss general health. This intervention also includes use of the SimpleMed+ electronic pillbox.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Participants in this group will talk with an interventionist to discuss general health. This intervention also includes use of the SimpleMed+ electronic pillbox.
Study: NCT06126510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)
Description: VG161:1.0×10\^8PFU/day, intratumoral injection administration for 3 consecutive days, 28 days as a cycle
Study: NCT06250478

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic ultrasound of the calf muscles
Description: Dynamic changes of the calf muscles during walking will be assessed in persons after stroke and compared to healthy controls

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dynamic ultrasound of the calf muscles
Description: Dynamic changes of the calf muscles during walking will be assessed in persons after stroke and compared to healthy controls
Study: NCT06277518

Intervention type: PROCEDURE
Intervention: Surgery for malignant tumors of the digestive system
Description: Related treatment or palliative surgery under general anesthesia for digestive system malignancies
Study: NCT04635085

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empowerment-based Cognitive behavioral therapy for insomnia for MCI
Description: Participants in the intervention group will participate in a 12-week empowerment-based CBT-I comprising face-to-face sessions supplemented with telephone follow-ups. In total, six face-to-face sessions (90 minutes/session) will be conducted in a small group format with 6-8 participants in a group.
Study: NCT05591170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 120 000 IU
Description: single, oral administration of high dose of vitamin D
Study: NCT06478576

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: multibranched stent graft system
Description: To evaluate the feasibility of multibranched stent graft system for Endovascular Treatment of Thoracoabdominal Aortic Aneurysm(TAAA)